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Abstract
Optoacoustic tomography has been used for the detection of pancreatic ductal
adenocarcinoma targeted by pH Low Insertion Peptide (pHLIP) conjugated to near infrared
fluorescent dye. It was proved that tumor targeting is a pH-dependent. The approach could
have major implication for detection and monitoring of pancreatic and other cancers.
Commentary on Kimbrough et al.
In this issue of Clinical Cancer Research, Kimbrough and colleagues (1) report that pH-sensitive
pHLIP variant 7 (V7) conjugated to near infrared fluorescent dye, Alexa750, targets pancreatic
ductal adenocarcinoma (PDAC) in human S2VP10 and S2013 pancreatic cancer xenograft mouse
models with minimal off-target accumulation. At the same time, pH-insensitive K7 pHLIP, where
a single protonatable Glu residue was replaced by a positively-charged Lys residue, served as a
control and showed about 100 times less tumor accumulation. Immediately prior to injection of
the constructs, as well as 4 and 24 hours post injection, mice were imaged by employing of
multispectral optoacoustic tomography (MSOT). Optoacoustic imaging is an emerging new
technology with the potential to increase sensitivity and improve spatial resolution. It
represents a hybrid technique that incorporates advantageous properties of both light and
sound, since resolution of the optical contrast obeys the rules of ultrasonic diffraction,
rendering photon scattering irrelevant to image resolution (2, 3). Thus, high-resolution at depth
of organ or tissue could be achieved in contrast to optical imaging, which is critical for the
imaging of tumors in humans.
To improve cancer detection it is very important to introduce new imaging modalities, which
should be accompanied with the development of novel tumor-specific molecular contrast
probes. There are number of ways of tumor targeting, one of the most popular is based on
targeting of overexpressed protein biomarkers. However, the genetic instability and
consequent heterogeneity of cancer cells limit approaches for treatment of tumors by targeting
specific biomarkers, since clonal selection leads cell populations to overcome the therapy by
growth of sub-populations that do not express sensitizing levels of the biomarker in question.
Cytotoxic therapies, whilst treating the majority of cancer cells, may spare multidrug resistant
clones leading to tumor relapse and treatment failure (4). Moreover, this transient
depopulation of sensitive tumor cells by chemotherapeutic agents may provide a growth
advantage to the surviving cells, leading to outgrowth of resistant clones (5). It is therefore
important to develop alternative approaches, which are based on targeting of tumor
microenvironment that is less likely to be subject to resistant selection. One such property is
the acidity that is associated with tumor growth and development, which could serve as a
universal marker for targeting. Adaptations to the highly acidic microenvironment are critical
steps in the transition from an avascular pre-invasive tumor to a malignant invasive carcinoma.
Although the acidity also varies within and among tumors, the general variation favors therapy,
since more aggressive and more metastatic tumors tend to be more acidic (6).
The promise of exploiting tumor acidosis as a cancer biomarker has not been fully realized in
clinical practice, even though the acidity has been a known property since the work of Otto

Warburg nearly a century ago. The problem has been to find a practical way to target acidity,
since the bulk extracellular pH in diseased tissue is just 0.5-0.8 pH units lower than the
extracellular pH in healthy tissue (7). From a biological standpoint the change is significant, and
alters the functions and survival of cells. At the same time, from a chemical standpoint the
change is small, so very precise tuning of chemical properties would be needed in a targeting
agent. But, an important to outline that the pH is lowest at the surfaces of cells compared to
the bulk extracellular pH and increases with distance from cellular membrane, and becoming
normal in the vicinity of blood vessels . So, the average pH in tissue is less informative than the
pH at cellular surfaces, which needs to be the main target for the development of pH-sensitive
agents.
One of the unique approaches introduced for the targeting of tumor acidity is based on the
biophysical principles of pH-dependent interaction of a polypeptide with lipid bilayer of a
membrane. pH Low Insertion Peptides capable to undergo a pH-induced membrane-associated
folding (8), which results in targeting of cancer cells in acidic tumors with minimal accumulation
in healthy tissue with normal extracellular pH (Figure 1). pHLIP peptides possess dual delivery
capabilities, making use of the energy of folding to translocate polar cargo molecules across
phospholipid bilayer of membrane and/or tether molecules to the cell surface. Also, the
process of peptide folding within a membrane ensures a high cooperativity of the transition,
which cannot be achieved by simple diffusion. Since pHLIPs are in equilibrium between
membrane bound and non-bound configurations at normal pH, they are capable of sensing pH
at the cell surface. As soon as pH drops (even on a half of pH unit), the Asp and Glu residues are
protonated and affinity of peptides to membrane is enhanced dramatically, which triggers
folding in membrane and release of energy. Depending on pHLIP sequence, protonatable
residues could be differently located on membrane surface, which directly affects the rate of
the protonation events at various pHs, and thus pK of peptides insertion into the membrane.
Family of pHLIP peptides with pK of insertion varying from 4.5 to 6.5 was introduced (9) and it
was confirmed that tumor targeting is indeed pH-dependent (10, 11). pHLIPs variant 7 (V7) and
variant 3 (V3) were selected as lead candidates for pH-specific delivery of imaging and
therapeutic agents to tumors of different origins. It was shown that the fluorescent pHLIPs can
localize and specifically detect pancreatic ductal adenocarcinoma in human xenografts as well
as PDAC and PanIN lesions in genetically engineered mouse models (12).

Kimbrough and colleagues also employed pHLIP variant 7 for the targeting of PDAC and
demonstrated that precise mapping of tumors could be achieved by optoacoustic imaging.
Pancreatic ductal adenocarcinoma remains highly lethal because of its advanced stage at
presentation. The lack of specific symptoms (due to the physical position of the organ), and the
lack of sensitive and specific biomarkers, make obtaining a diagnosis difficult at an early stage.
For these reasons, there is an urgent need for tools to aid in the early and specific detection of
PDAC prior to the development of micro-metastatic disease. The molecular imaging with
targeted probes could potentially improve the early diagnosis, staging, and monitoring of PDAC.
Endoscopic, laparoscopic, or handheld applications of MSOT in combination with pH-sensitive
pHLIP probes could aid in the detection and staging of pancreatic tumors, help determine

resectability, assist in identification of viable tumor during surgical intervention, as well as help
monitor responses to treatment.
Translation of pHLIP technology and MSOT imaging to clinics may lead to improvements in
imaging, treatment, and monitoring outcome of therapy for tumors of various origins,
especially highly aggressive and metastatic ones.
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Figure Legend
Schematic presentation of pHLIP peptide (red) conjugated with fluorescent dye (yellow)
interaction with plasma membrane of a normal cell in healthy tissue (A) and a cancer cell in
tumor (B). The extracellular pH in healthy tissue is around pH7.4. On the other hand, pH
gradient exists near the surface of cancer cells: the pH near the plasma membrane is lowest
(around pH6.0-6.2) increasing with distance from the membrane. pHLIP peptides are weakly
bound to the surface of cell membrane in healthy tissue. However, at low extracellular pH in
tumors, pHLIPs insert into plasma membrane, tethering imaging probe to cancer cells. In
tumors, the equilibrium is shifted toward membrane inserted form of the peptide, leading to
accumulation of the peptide and imaging agent within a tumor. At the same time, in healthy
tissue, the equilibrium is shifted toward membrane non-bound form of the peptide, which
results in washing of the peptide from healthy tissue.
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